about
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialPromising therapies for treatment of nonalcoholic steatohepatitis.MR Elastography of Liver Disease: State of the Art.Pathogenesis of non-alcoholic fatty liver disease.Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in miceA novel small compound that promotes nuclear translocation of YB-1 ameliorates experimental hepatic fibrosis in mice.Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway.Gene modulation for treating liver fibrosisBioconjugation of oligonucleotides for treating liver fibrosis.Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in vivo and in vitro.Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.Functional Immune Anatomy of the Liver-As an Allograft.A complex role of activin A in non-alcoholic fatty liver disease.Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model.Lower aldosterone-renin ratio is a risk factor for total and cancer death in Japanese individuals: the Takahata study.MicroRNA-30a ameliorates hepatic fibrosis by inhibiting Beclin1-mediated autophagy.A traditional formula, Chunggan extract, attenuates thioacetamide-induced hepatofibrosis via GSH system in rats.Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis.Magnetic resonance elastography: basic principles, technique, and clinical applications in the liverEffect of autophagy-associated proteins on the arecoline-induced liver injury in mice
P2860
Q24656131-AEE99410-CF41-4A9E-A046-AD65613390D0Q30248578-42EA7CD5-E485-4D2B-8BB4-8D96A91D85C6Q30403258-2613A5E1-63C0-4A1B-8995-4F76B6F2265CQ33606303-B5E4027A-FA08-462F-9EF6-82BD7BEEEDA2Q33622449-F1C65049-A29B-4D8C-BD31-820C25932229Q34575731-ABB06220-DFD1-4073-8F55-3CA30324E43FQ34985947-9A083E21-162E-4042-ADF4-E1164A16A501Q35649473-97B4C056-E7B5-48BD-9622-DDB442D2DA31Q35740215-CEBF43C3-8DD7-4D69-9CE6-25126A050894Q36921638-89DEB507-F495-4215-8AFC-B049E8962492Q37043515-5B228DA0-FF02-4798-A426-E1EA4184F589Q37118860-A9E80224-DD6C-43FC-AB1B-89057C1621D0Q37240434-DB2A6F8D-4D12-4FE7-AE76-0BBDC4020936Q37375539-512A9BEC-AF33-448A-9963-293F5C2FB281Q38723925-B3AF93E4-6AD5-4495-BC17-984319A0FA62Q39837123-D873CDC7-2BFC-4426-8454-2D12ECEC273CQ40211269-BEDDEAC9-A23E-41E6-9E66-B55C9E00D317Q40293690-A0246D89-270A-44E8-B869-8F0A2D40778AQ41717263-4BEE080C-D5B5-4735-8054-32848FB2A18CQ47167414-14330124-DD11-4416-BD64-6FDF25E632F6Q47344534-4AE25F2B-F90D-45EB-8A32-AD27FF9F55D5Q53072949-67C74F61-B3AB-4D89-8A43-8826EA8AA1F3Q57066240-11784964-D139-484A-81AB-65DABBE5BF84Q58802798-C786444A-D316-42A7-880E-EB6982DA5E7C
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Antifibrotic agents for liver disease.
@ast
Antifibrotic agents for liver disease.
@en
type
label
Antifibrotic agents for liver disease.
@ast
Antifibrotic agents for liver disease.
@en
prefLabel
Antifibrotic agents for liver disease.
@ast
Antifibrotic agents for liver disease.
@en
P2860
P1476
Antifibrotic agents for liver disease.
@en
P2093
Friedman SL
P2860
P356
10.1111/J.1600-6143.2005.01143.X
P407
P577
2006-01-01T00:00:00Z